Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 2/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598258 | 0.89 | HTT (0.76) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL3462425 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL28105261 | 0.88 | RAB9A (0.73) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL10039357 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL7698230 | 0.85 | KMT2A (0.68) | SMN1; SMN2HPGDRAB9AMEN1KMT2A | |
| SCHEMBL15031530 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL3462627 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL3461653 | 0.83 | RAB9A (0.63) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL16598059 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 | |
| SCHEMBL23894866 | 0.82 | SMN1; SMN2 (0.75) | SMN1; SMN2CYP1A2CYP2C19HPGDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240748-A1 | IMPROVED METHOD FOR THE FORMATION OF AMIDES | BASF SE (DE) | 2024-11-28 | — | — | WO | disclosed |
| US-20240093191-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2024-03-21 | — | — | US | disclosed |
| EP-3976601-B1 | MICROBIOCIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-4288539-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | Research Institute at Nationwide Children's Hospital (US) | 2023-12-13 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | SMN1; SMN2 4557/4885CYP1A2 3108/4885CYP2C19 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.